智通财经APP讯，中国医疗集团(08225)发布截至2025年6月30日止六个月中期业绩，营业收入2162万元 (人民币，下同)，同比增加18.19%;股东应占溢利869.9万元，同比增加18.31%;每股基本盈利0.87分。 ...

[Company Information](index=1&type=section&id=Company%20Information) [GEM Listing Characteristics and Directors' Responsibility Statement](index=1&type=section&id=GEM%20Listing%20Characteristics%20and%20Directors'%20Responsibility%20Statement) This announcement highlights the higher investment risk of the HKEX GEM market and states that the company's directors bear full responsibility for the accuracy, completeness, and non-misleading nature of the announcement's content - The GEM market is positioned as a listing platform for high-investment-risk companies, and investors should carefully consider potential risks[1](index=1&type=chunk) - The company's directors jointly and individually confirm that the information contained in this announcement is accurate, complete, and not misleading in all material respects[2](index=2&type=chunk) [Interim Results Summary](index=2&type=section&id=Interim%20Results%20Summary) [Summary of Financial Performance for H1 2025](index=2&type=section&id=Summary%20of%20Financial%20Performance%20for%20H1%202025) For the six months ended June 30, 2025, China Medical Group achieved approximately 18% growth in revenue and profit before tax, with stable gross margin, but the board does not recommend a dividend 2025 H1 Key Financial Indicators | Indicator | 2025 H1 (RMB) | 2024 H1 (RMB) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Revenue | 21,620,241 | 18,293,013 | 18.19% | | Profit Before Tax | 10,234,000 | 8,651,000 | 18.30% | | Gross Profit | 13,945,000 | 11,982,000 | 16.38% | | Gross Profit Margin | 64.5% | 65.5% | -1.0% | - The Board recommends not to declare any dividend for the six months ended June 30, 2025[3](index=3&type=chunk) [Condensed Consolidated Financial Statements](index=3&type=section&id=Condensed%20Consolidated%20Financial%20Statements) [Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited)](index=4&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income%20(Unaudited)) For the six months ended June 30, 2025, the Group's revenue and operating profit both saw significant growth, with net profit up 18.31% year-on-year, and basic and diluted EPS at 0.87 cents Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited) | Indicator | 2025 (RMB thousand) | 2024 (RMB thousand) | | :--- | :--- | :--- | | Revenue | 21,620 | 18,293 | | Cost of Sales | (7,675) | (6,311) | | Staff Costs | (2,330) | (2,280) | | Administrative Expenses | (1,389) | (1,040) | | Operating Profit | 10,230 | 8,666 | | Profit Before Tax | 10,234 | 8,651 | | Net Profit for the Period | 8,699 | 7,353 | | Earnings Per Share (Basic and Diluted) | 0.87 cents | 0.74 cents | [Condensed Consolidated Statement of Financial Position (Unaudited)](index=5&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position%20(Unaudited)) As of June 30, 2025, the Group's total assets and net assets increased, with a significant rise in trade receivables within current assets, while trade payables decreased Condensed Consolidated Statement of Financial Position (Unaudited) | Indicator | June 30, 2025 (RMB thousand) | December 31, 2024 (RMB thousand) | | :--- | :--- | :--- | | Non-Current Assets | 8,016 | 8,324 | | Current Assets | 102,003 | 92,636 | | Trade and Bills Receivables | 63,778 | 57,584 | | Cash and Cash Equivalents | 23,732 | 14,194 | | Current Liabilities | 31,603 | 31,243 | | Trade Payables, Other Payables and Accrued Charges | 5,623 | 8,298 | | Net Current Assets | 70,400 | 61,393 | | Net Assets | 78,416 | 69,717 | | Total Equity | 78,416 | 69,717 | [Condensed Consolidated Statement of Cash Flows (Unaudited)](index=6&type=section&id=Condensed%20Consolidated%20Statement%20of%20Cash%20Flows%20(Unaudited)) For the six months ended June 30, 2025, the Group's net cash generated from operating activities significantly increased, with cash and cash equivalents at period-end reaching RMB 23,732 thousand Condensed Consolidated Statement of Cash Flows (Unaudited) | Indicator | 2025 H1 (RMB thousand) | 2024 H1 (RMB thousand) | | :--- | :--- | :--- | | Net Cash Generated from Operating Activities | 9,538 | 2,883 | | Net Cash Used in Investing Activities | 0 | (165) | | Net Cash Used in Financing Activities | 0 | 0 | | Net Increase in Cash and Cash Equivalents | 9,538 | 2,718 | | Cash and Cash Equivalents at End of Period | 23,732 | 6,858 | [Condensed Consolidated Statement of Changes in Equity (Unaudited)](index=7&type=section&id=Condensed%20Consolidated%20Statement%20of%20Changes%20in%20Equity%20(Unaudited)) As of June 30, 2025, the Group's total equity increased to RMB 78,416 thousand, primarily due to the contribution from net profit for the period Condensed Consolidated Statement of Changes in Equity (Unaudited) | Indicator | June 30, 2025 (RMB thousand) | June 30, 2024 (RMB thousand) | | :--- | :--- | :--- | | Total Equity at Beginning of Period | 69,717 | 84,183 | | Net Profit for the Period | 8,699 | 7,353 | | Total Equity at End of Period | 78,416 | 91,536 | [Notes to the Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) [General Information](index=8&type=section&id=General%20Information) China Medical Group Company Limited, incorporated in Cayman Islands and listed on HKEX, primarily provides one-stop integrated pharmaceutical services in China, aiming to become a comprehensive medical terminal service group under an internet architecture - The Company was incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange on July 10, 2003[13](index=13&type=chunk) - The principal business is to provide one-stop integrated pharmaceutical services in China, including clinical research, post-marketing surveillance, real-world studies, medical research activities, medical marketing services, and other pharmaceutical services[13](index=13&type=chunk) - The Group is committed to becoming a comprehensive medical terminal service group under an internet architecture[13](index=13&type=chunk) [Statement of Compliance with New and Revised International Financial Reporting Standards](index=8&type=section&id=Statement%20of%20Compliance%20with%20New%20and%20Revised%20International%20Financial%20Reporting%20Standards) The company complies with new and revised HKFRSs issued by HKICPA, effective January 1, 2025, which have not caused significant changes to accounting policies, financial statement presentation, or reported amounts - The Company complies with the new and revised Hong Kong Financial Reporting Standards (HKFRSs) issued by the Hong Kong Institute of Certified Public Accountants (HKICPA) relevant to its Hong Kong operations, effective January 1, 2025[13](index=13&type=chunk) - The adoption of the new and revised HKFRSs has not caused significant changes to the Company's accounting policies, financial statement presentation, or reported amounts for the current and prior periods[13](index=13&type=chunk) [Accounting Policies and Basis of Presentation](index=8&type=section&id=Accounting%20Policies%20and%20Basis%20of%20Presentation) The condensed consolidated financial statements are prepared in RMB according to applicable HKFRSs, HK GAAP, GEM Listing Rules, and Hong Kong Companies Ordinance - The unaudited condensed consolidated financial statements are prepared in accordance with all applicable Hong Kong Financial Reporting Standards issued by the HKICPA, Hong Kong Generally Accepted Accounting Principles, the applicable disclosure provisions of the GEM Listing Rules, and the disclosure requirements of the Hong Kong Companies Ordinance[15](index=15&type=chunk) - The unaudited condensed consolidated financial statements for the current period are presented in RMB, which is also the functional currency of the Group[16](index=16&type=chunk) [Revenue](index=9&type=section&id=Revenue) The Group primarily engages in research, development, academic promotion, and clinical registration services, with total revenue increasing by 18.19% year-on-year, 100% from Post-Marketing Surveillance (PMS) services - The Group is principally engaged in research, development, academic promotion, and clinical registration services[17](index=17&type=chunk) Revenue Composition | Revenue Category | 2025 (RMB thousand) | 2024 (RMB thousand) | | :--- | :--- | :--- | | Post-Marketing Surveillance (PMS) | 21,620 | 18,293 | | **Total Revenue** | **21,620** | **18,293** | - The Group's total revenue for the current period increased by **18.19%** compared to the same period in 2024, with PMS revenue increasing by approximately **18.19%**[18](index=18&type=chunk) [Administrative Expenses](index=9&type=section&id=Administrative%20Expenses) Administrative expenses for the period were RMB 1,389 thousand, a 33.56% increase from the same period in 2024 Administrative Expenses | Indicator | 2025 (RMB thousand) | 2024 (RMB thousand) | | :--- | :--- | :--- | | Administrative Expenses | (1,389) | (1,040) | - Administrative expenses increased by **33.56%** compared to the same period in 2024[20](index=20&type=chunk) [Earnings Per Share](index=10&type=section&id=Earnings%20Per%20Share) Basic and diluted earnings per share for the period were 0.87 cents, up from 0.74 cents in the prior year, mainly due to increased net profit attributable to company owners - Basic earnings per share are calculated by dividing the unaudited net profit attributable to owners of the Company of approximately **RMB 8,699,000** (2024: RMB 7,353,000) by the weighted average number of ordinary shares of the Company, which is **995,351,660** shares for the period[21](index=21&type=chunk) Earnings Per Share | Indicator | 2025 (cents) | 2024 (cents) | | :--- | :--- | :--- | | Basic Earnings Per Share | 0.87 | 0.74 | | Diluted Earnings Per Share | 0.87 | 0.74 | [Taxation](index=10&type=section&id=Taxation) The Group had no taxable profit in Hong Kong, with China corporate income tax rates ranging from 9%-25%, and some subsidiaries benefiting from a 15% preferential tax rate due to tax incentives - The Group did not generate any taxable profit in Hong Kong during the period, thus no provision for Hong Kong profits tax was made[22](index=22&type=chunk) - China corporate income tax rates range from **9%-25%**, and some subsidiaries enjoy a **15%** preferential income tax rate due to being located in tax-preferential regions and belonging to industries eligible for tax incentives[22](index=22&type=chunk) [Dividends](index=10&type=section&id=Dividends) The Board does not recommend the payment of any dividend for the six months ended June 30, 2025 - The Board does not recommend the payment of any dividend for the current period (2024: nil)[23](index=23&type=chunk) [Trade and Bills Receivables](index=11&type=section&id=Trade%20and%20Bills%20Receivables) As of June 30, 2025, total trade and bills receivables increased to RMB 63,778 thousand, with a significant increase in amounts aged 7 to 12 months Trade and Bills Receivables Aging Analysis | Aging | June 30, 2025 (RMB thousand) | December 31, 2024 (RMB thousand) | | :--- | :--- | :--- | | Within 6 months | 21,689 | 27,401 | | 7 to 12 months | 27,022 | 6,043 | | 13 to 18 months | 5,185 | 5,947 | | 19 to 24 months | 4,582 | 1,225 | | 25 to 30 months | 1,225 | 0 | | Over 36 months | 4,075 | 16,968 | | **Total** | **63,778** | **57,584** | [Trade and Other Payables and Accrued Charges](index=11&type=section&id=Trade%20and%20Other%20Payables%20and%20Accrued%20Charges) As of June 30, 2025, total trade payables decreased to RMB 5,623 thousand, primarily due to a significant reduction in payables aged over 36 months Trade Payables Aging Analysis | Aging | June 30, 2025 (RMB thousand) | December 31, 2024 (RMB thousand) | | :--- | :--- | :--- | | Within 30 days | 6 | 81 | | 31 to 90 days | 17 | 0 | | 91 to 365 days | 51 | 58 | | Over 365 days | 5,549 | 8,159 | | **Total** | **5,623** | **8,298** | [Management Discussion and Analysis](index=13&type=section&id=Management%20Discussion%20and%20Analysis) [Business Review](index=13&type=section&id=Business%20Review) China Medical Group provides full-chain services from drug R&D to sales, focusing on Post-Marketing Surveillance (PMS) and Real-World Study (CHG RWS), building core capabilities through RWD, RWS, and AI to become a leader in real-world clinical research services - The Group provides full-chain services from drug research and development to market sales, initially focusing on Pharmaceutical Development Services (PDS), registration, and pre-market clinical research, and later gradually focusing on Post-Marketing Surveillance (PMS), especially Real-World Study (CHG RWS)[27](index=27&type=chunk) - The Group's business vision is to become a leader in real-world clinical research services, focusing on five major areas: mental and psychological disorders, neurological disorders, allergic diseases, rare diseases, and viral infectious diseases[27](index=27&type=chunk) - This business vision is achieved through the construction of three core capabilities: Real-World Data (RWD), Real-World Study (RWS), and Artificial Intelligence (AI)[27](index=27&type=chunk) - In the first half of 2025, the Group's business developed steadily, with strong demand for post-marketing CRSO services, and the establishment of a biosample testing laboratory to serve clinical research[28](index=28&type=chunk) [Financial Review](index=14&type=section&id=Financial%20Review) For the six months ended June 30, 2025, the Group's revenue, profit before tax, and net profit all achieved approximately 18% year-on-year growth, while total administrative expenses and staff costs increased by 12.02% 2025 H1 Financial Performance | Indicator | 2025 H1 (RMB) | 2024 H1 (RMB) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Revenue | 21,620,241 | 18,293,013 | 18.19% | | Profit Before Tax | 10,234,000 | 8,651,000 | 18.30% | | Net Profit | 8,699,000 | 7,353,000 | 18.31% | | Total Administrative Expenses and Staff Costs | 3,719,000 | 3,320,000 | 12.02% | - Revenue from post-marketing medical clinical services, clinical research, medical liaison, and medical marketing services accounted for **100%** of total revenue[30](index=30&type=chunk) [Liquidity, Financial Resources, and Gearing Ratio](index=14&type=section&id=Liquidity,%20Financial%20Resources,%20and%20Gearing%20Ratio) As of June 30, 2025, the Group's net current assets and net assets both increased, funding operations through self-generated working capital with no borrowings, making the gearing ratio inapplicable. Future funding will consider various methods to support development Liquidity Indicators | Indicator | June 30, 2025 (RMB) | December 31, 2024 (RMB) | | :--- | :--- | :--- | | Net Current Assets | 70,400,000 | 61,393,000 | | Net Assets | 78,416,000 | 69,717,000 | - The Group funds its operations through its own working capital and has no borrowings, thus the gearing ratio is not applicable[31](index=31&type=chunk) - The Group will consider further fundraising through bank loans, new share issues, convertible notes, new bond issues, and other methods to meet working capital and long-term funding needs for future development[32](index=32&type=chunk) [Outlook](index=15&type=section&id=Outlook) Facing current pharmaceutical industry challenges, the Group aims to achieve breakthrough growth through innovative business models, digital medical capabilities, specialized field breakthroughs, brain science research, and big data labs, while building digital specialized clinics [Unicorn Business Model in New Blue Ocean Market](index=15&type=section&id=Unicorn%20Business%20Model%20in%20New%20Blue%20Ocean%20Market) The Group launched "RWS-Therapy" and "D-CRCO" models, leveraging big data clinical research and digital technology to redefine treatment and commercialization - Launched the "Research-Oriented Therapy RWS-Therapy Model" to conduct big data research on five major specialties' clinical conditions and diseases through real-world clinical studies, guiding medication treatment[34](index=34&type=chunk) - Launched the "Digital Clinical Research-Oriented Promotion D-CRCO Model" to precisely empower product commercialization using big data clinical research[34](index=34&type=chunk) [Building Digital Medical Combat Power](index=15&type=section&id=Building%20Digital%20Medical%20Combat%20Power) The Group will build a comprehensive medical terminal service complex, supported by intelligent digital and medical technologies, covering the entire scenario from R&D to patient recovery, forming a closed-loop system - Building a comprehensive medical terminal service complex supported by intelligent digital and medical technologies, covering the entire scenario from R&D to patients[35](index=35&type=chunk) - Forming a closed-loop system from scientific research to rehabilitation and cure, encompassing hospital big data clinical research, digital scientific research product promotion, digital R&D-oriented clinical research specialties, special medical drug diagnosis, and rehabilitation tourism medical services[35](index=35&type=chunk) [Breakthrough in Healing - Becoming a Leading Research and Academic Institution in Anti-Allergy](index=15&type=section&id=Breakthrough%20in%20Healing%20-%20Becoming%20a%20Leading%20Research%20and%20Academic%20Institution%20in%20Anti-Allergy) The Group aims to be a global anti-allergy center, providing services from clinical research to commercial pharmacy zones, collaborating with institutions, and utilizing RWS-THERAPY and CRCO platforms for post-marketing real-world clinical research - The Group's BaiMin Anti-Allergy Center is committed to becoming a global leading anti-allergy center, providing services in the anti-allergy field from clinical research to commercial pharmacy BaiMin specialty zones[36](index=36&type=chunk) - Collaborating with multiple medical institutions and large chains to establish BaiMin Allergy Prevention and Treatment Specialties and BaiMin Anti-Allergy Zones; currently, more than six out of ten anti-allergy drugs are completed by the BaiMin Clinical Research Center[36](index=36&type=chunk) - Utilizing RWS-THERAPY and CRCO platforms to conduct post-marketing real-world clinical research, assisting enterprises in digital academic promotion[36](index=36&type=chunk) [Pioneer in Brain Science Research and Digital Academic Promotion](index=15&type=section&id=Pioneer%20in%20Brain%20Science%20Research%20and%20Digital%20Academic%20Promotion) The Group has extensive experience in brain science, particularly Alzheimer's research, and is committed to clinical and big data research in stroke dementia, epilepsy, Parkinson's, and ALS, aiming to leverage these strengths for more projects - The XiEn Anti-Dementia Research Group has participated in clinical research for **80%** of products in this field, including Donepezil, Memantine, Rivastigmine, and traditional Chinese medicine[37](index=37&type=chunk) - The XiEn Brain Science Digital Clinical Research Center has long been committed to clinical and big data research in stroke dementia, epilepsy, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS), participating in or organizing over **60%** of major national brain science clinical research projects[37](index=37&type=chunk)[38](index=38&type=chunk) [Big Data Lab for New Drug Discovery and Medication Guidance](index=16&type=section&id=Big%20Data%20Lab%20for%20New%20Drug%20Discovery%20and%20Medication%20Guidance) The Group's "RWS Wanquan Center" plans to re-screen and combine existing drugs through big data real-world clinical research to find optimal treatment plans, such as studying how drugs like Yueting prevent stroke, COPD, cardiovascular disease, and lung cancer - The "RWS Wanquan Center" plans to re-screen and combine existing drugs through big data real-world clinical research to find optimal treatment plans[39](index=39&type=chunk) - Researching how drugs like Yueting prevent diseases such as stroke, COPD, cardiovascular disease, and lung cancer in tobacco addiction[39](index=39&type=chunk) [Building Digital Specialty Clinics](index=16&type=section&id=Building%20Digital%20Specialty%20Clinics) The Group collaborates with top medical institutions and leading pharmacy chains to establish research-digital specialty clinics and zones, including Yueting Smoking Cessation, XiEn Psychology, BaiMin Fever & Cough, and Antiviral Drug Research & Treatment, with plans to expand to more hospitals and cloud institutions - Established research-digital specialty clinics and zones with multiple top medical institutions in Beijing, Shanghai, Guangzhou, and leading pharmacy chains and digital medical groups such as Gaoji Medical, Neptune Chain, Weiyi Group, and Miaoshou Medical[40](index=40&type=chunk) - Specialty zones include Yueting Smoking Cessation Research and Treatment, XiEn Psychology Research and Treatment, BaiMin Fever & Cough Research and Treatment, and Antiviral Drug Research and Treatment[40](index=40&type=chunk) - Plans to launch Group-branded specialty clinics and Wanquan specialty pharmacy zones in more hospitals and cloud institutions[41](index=41&type=chunk) [Dividends](index=16&type=section&id=Dividends) The Board does not recommend the payment of any dividend for the six months ended June 30, 2025 - The Board does not recommend the payment of any dividend for the six months ended June 30, 2025 (2024: nil)[42](index=42&type=chunk) [Material Investments](index=16&type=section&id=Material%20Investments) There were no material investments during the period - Other than as disclosed in this announcement, there were no material investments during the period (2024: nil)[43](index=43&type=chunk) [Material Commitments](index=16&type=section&id=Material%20Commitments) As of June 30, 2025, the Group had no material capital commitments - As of June 30, 2025, the Group had no material capital commitments (December 31, 2024: nil)[44](index=44&type=chunk) [Material Acquisitions and Disposals of Subsidiaries and Associates](index=16&type=section&id=Material%20Acquisitions%20and%20Disposals%20of%20Subsidiaries%20and%20Associates) During the period, the Group did not undertake any material acquisitions or disposals of subsidiaries and associates - During this period, the Group did not undertake any material acquisitions or disposals of subsidiaries and associates (2024: nil)[45](index=45&type=chunk) [Pledges of Assets](index=17&type=section&id=Pledges%20of%20Assets) As of June 30, 2025, the Group had no available banking facilities or pledges of any assets - As of June 30, 2025, the Group had no available banking facilities (December 31, 2024: RMB 0)[46](index=46&type=chunk) - As of June 30, 2025, the Group had no pledges of any assets (2024: nil)[47](index=47&type=chunk) [Contingent Liabilities](index=17&type=section&id=Contingent%20Liabilities) As of June 30, 2025, the Group had no material contingent liabilities - As of June 30, 2025, the Group had no material contingent liabilities (2024: nil)[48](index=48&type=chunk) [Capital Structure](index=17&type=section&id=Capital%20Structure) The company's capital structure remained unchanged during the period, with approximately 995,351,660 shares issued - The company's capital structure (including ordinary shares and capital reserves) remained unchanged during the period[49](index=49&type=chunk) - As of June 30, 2025, approximately **995,351,660** shares were issued[49](index=49&type=chunk) [Future Plans for Material Investments or Capital Assets](index=17&type=section&id=Future%20Plans%20for%20Material%20Investments%20or%20Capital%20Assets) Other than those disclosed, the Group has no future plans for material investments or capital assets - Other than those disclosed in this announcement, the Group has no future plans for material investments or capital assets[50](index=50&type=chunk) [Foreign Exchange Risk](index=17&type=section&id=Foreign%20Exchange%20Risk) The Group's transactions are predominantly denominated in RMB, and foreign currency risk is closely monitored, with hedging undertaken when necessary - During the review period, the vast majority of the Group's transactions were denominated in RMB[51](index=51&type=chunk) - The Group closely monitors its foreign currency risk from time to time and will undertake appropriate hedging when necessary[51](index=51&type=chunk) [Financial Policy](index=17&type=section&id=Financial%20Policy) The Board will continue to follow a prudent policy in managing cash and maintaining strong liquidity to capitalize on future growth opportunities - The Board will continue to follow a prudent policy in managing the Group's cash and maintaining strong and healthy liquidity[52](index=52&type=chunk) - This ensures the Group can fully capitalize on future growth opportunities[52](index=52&type=chunk) [Events After Reporting Period](index=17&type=section&id=Events%20After%20Reporting%20Period) As of the announcement date, there have been no significant subsequent events for the Company or the Group after June 30, 2025 - There have been no significant subsequent events for the Company or the Group from June 30, 2025, up to the date of this announcement[53](index=53&type=chunk) [Human Resources](index=18&type=section&id=Human%20Resources) [Employees and Remuneration Policy](index=18&type=section&id=Employees%20and%20Remuneration%20Policy) The Group's remuneration policy is based on individual performance, offering benefits such as salaries, bonuses, medical care, pension contributions, and share option schemes. As of June 30, 2025, total employees were 44, with total salaries of approximately RMB 2,330,000 - The Group's remuneration policy is primarily determined by individual employee performance, offering benefits such as salaries, bonuses, medical and pension contributions, and a share option scheme[54](index=54&type=chunk)[56](index=56&type=chunk) - As of June 30, 2025, the Group had a total of **44** employees, and total salaries for the period, including those of employees and directors, amounted to approximately **RMB 2,330,000** (2024: approximately RMB 2,280,000)[56](index=56&type=chunk) - The Group provides employees with training and development opportunities and utilizes a share option scheme to incentivize eligible participants[55](index=55&type=chunk)[57](index=57&type=chunk) [Other Information](index=18&type=section&id=Other%20Information) [Purchase, Sale or Redemption of the Company's Shares](index=18&type=section&id=Purchase,%20Sale%20or%20Redemption%20of%20the%20Company's%20Shares) Neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed shares during the period - Neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed shares during this period[59](index=59&type=chunk) [Competing Interests](index=18&type=section&id=Competing%20Interests) As of June 30, 2025, none of the Company's directors, management shareholders, or their associates had any interests in businesses that compete or may compete with the Group's business - As of June 30, 2025, none of the Company's directors or management shareholders and their respective associates had any interests in businesses that compete or may compete with the Group's business[60](index=60&type=chunk) [Directors' and Chief Executive's Interests and Short Positions in Shares, Underlying Shares and Debentures of the Company and Any Associated Corporations](index=18&type=section&id=Directors'%20and%20Chief%20Executive's%20Interests%20and%20Short%20Positions%20in%20Shares,%20Underlying%20Shares%20and%20Debentures%20of%20the%20Company%20and%20Any%20Associated%20Corporations) As of June 30, 2025, directors and the chief executive held interests in the shares, underlying shares, and debentures of the Company and its associated corporations, with Mr. Guo Xia holding approximately 72.70% of the total share interest Directors' and Chief Executive's Share Interests | Name | Capacity | Number of Shares (excluding equity derivatives) | Number of Shares held under physically settled equity derivatives | Total Number of Shares | Approximate Percentage of Interest (%) | | :--- | :--- | :--- | :--- | :--- | :--- | | Guo Xia | Beneficial Owner | 114,701,941 | 18,150,000 | 132,851,941 | 13.35% | | Guo Xia | Controlled Corporation Interest | 590,716,637 | - | 590,716,637 | 59.35% | | Former Director Song Xuemei | Beneficial Owner | 6,500 | 410,000 | 416,500 | 0.04% | | Zhang Li | Beneficial Owner | 960,000 | - | 960,000 | 0.96% | | Ni Binhui | Beneficial Owner | 100,000 | 100,000 | 200,000 | 0.02% | | Former Director Qiu Rui | Beneficial Owner | - | 120,000 | 120,000 | 0.01% | | Former Director Zhen Ling | Beneficial Owner | - | 100,000 | 100,000 | 0.01% | - Mr. Guo Xia is deemed to have substantial share interests through his wholly-owned entities, Winsland Agents Limited and Venturepharm Holdings Inc[63](index=63&type=chunk) [Substantial Shareholders' Interests](index=21&type=section&id=Substantial%20Shareholders'%20Interests) As of June 30, 2025, Winsland Agents Limited and Venturepharm Holdings Inc. were substantial shareholders, holding 35.10% and 15.01% (beneficial owner) of the Company's shares, respectively, directly or indirectly Substantial Shareholders' Share Interests | Name | Capacity | Number of Shares | Percentage of Interest | | :--- | :--- | :--- | :--- | | Winsland Agents Limited | Beneficial Owner | 349,368,873 | 35.10% | | Winsland Agents Limited | Controlled Corporation Interest | 241,347,764 | 24.25% | | Bright Excel Assets Limited | Beneficial Owner | 91,915,181 | 9.23% | | Venturepharm Holdings Inc. | Beneficial Owner | 149,432,583 | 15.01% | | Venturepharm Holdings Inc. | Controlled Corporation Interest | 91,915,181 | 9.23% | - Winsland Agents Limited and Venturepharm Holdings Inc. are deemed to have interests in the shares of Bright Excel Assets Limited[66](index=66&type=chunk) [Directors' Rights to Acquire Shares or Debentures](index=21&type=section&id=Directors'%20Rights%20to%20Acquire%20Shares%20or%20Debentures) Other than the disclosed share option scheme, there were no arrangements during the period enabling directors or their associates to subscribe for shares or debentures of the Company or its associated corporations - Other than the disclosed share option scheme, at no time during the period was the Company, its holding company, or any of its subsidiaries or associated corporations a party to any arrangement that would enable the Company's directors and chief executive or their respective associates to subscribe for shares or debentures of the Company or any associated corporation, or to obtain benefits by acquiring shares or debentures of the Company or any other body corporate[67](index=67&type=chunk) [Share Option Scheme](index=22&type=section&id=Share%20Option%20Scheme) [Purpose of the Share Option Scheme](index=22&type=section&id=Purpose%20of%20the%20Share%20Option%20Scheme) The Share Option Scheme aims to acknowledge qualified participants' contributions, offer opportunities to own company shares, incentivize performance, attract and retain talent, and promote the Group's long-term development - The Share Option Scheme aims to acknowledge the contributions and potential contributions that eligible participants have made or may make to the Group[70](index=70&type=chunk) - It provides eligible participants with an opportunity to own individual shares in the Company, thereby incentivizing their performance and efficiency, attracting and retaining talent, and benefiting the Group's long-term development[70](index=70&type=chunk) [Eligible Participants](index=22&type=section&id=Eligible%20Participants) Eligible participants include the Group's directors, employees, consultants, contractors, and beneficiaries of discretionary trusts or beneficial owners of entities, as determined by the Board - Eligible participants include any director, employee (whether full-time or part-time), consultant, advisor, or contractor of the Group, or any entity in which any member of the Group holds an interest[68](index=68&type=chunk) - This also includes any discretionary trust whose discretionary objects include any director, employee, consultant, or contractor of the Group or any invested entity; and any beneficial owner company of any director, employee, consul, or contractor of the Group or any invested entity[68](index=68&type=chunk) [Exercise Price of Share Options](index=22&type=section&id=Exercise%20Price%20of%20Share%20Options) The exercise price of share options must not be less than the highest of the closing price on the offer date, the average closing price of the preceding five business days, and the nominal value of the share - The exercise price of share options shall not be less than the highest of: (i) the closing price of the shares as stated in the daily quotation sheet of the Stock Exchange on the offer date of the specific option; (ii) the average closing price for the five business days immediately preceding the offer date of the specific option; and (iii) the nominal value of the shares on the offer date of the specific option[69](index=69&type=chunk) [Maximum Number of Shares Available for Subscription Under the Share Option Scheme](index=23&type=section&id=Maximum%20Number%20of%20Shares%20Available%20for%20Subscription%20Under%20the%20Share%20Option%20Scheme) The total number of shares under the Share Option Scheme is limited to 30% of issued shares, with an initial scheme mandate limit of 10%, which can be refreshed by shareholders' approval up to 10% of issued shares - The total limit on the number of shares that may be issued upon the exercise of all granted and outstanding options shall not exceed **30%** of the issued shares (the Scheme Limit)[71](index=71&type=chunk) - The scheme mandate limit is **10%** of the total number of issued shares as of the date of approval of the Share Option Scheme[71](index=71&type=chunk) - The Company may, with the approval of shareholders in a general meeting, refresh the scheme mandate limit at any time, provided that the refreshed limit does not exceed **10%** of the issued shares as of the date of approval[71](index=71&type=chunk) [Maximum Entitlement for Each Eligible Participant](index=23&type=section&id=Maximum%20Entitlement%20for%20Each%20Eligible%20Participant) Unless approved by shareholders, the total number of shares issued and to be issued upon exercise of options granted to each eligible participant in any 12-month period shall not exceed 1% of the issued shares - Unless approved by shareholders, the total number of shares issued and to be issued upon the exercise of options granted to each eligible participant (including both exercised and outstanding options) in any 12-month period shall not exceed **1%** of the issued shares[72](index=72&type=chunk) - The total number of shares available for issue under the share option scheme is **88,947,166** shares, representing **8.94%** of the total issued shares as of the date of this interim results announcement[72](index=72&type=chunk) [Performance Targets](index=23&type=section&id=Performance%20Targets) Unless otherwise determined by the Board, there are no performance targets that must be met or achieved before exercising options - Unless otherwise determined by the Board, there are no performance targets that must be met or achieved before exercising the options[73](index=73&type=chunk) [Minimum Period for Holding Options](index=23&type=section&id=Minimum%20Period%20for%20Holding%20Options) Unless otherwise determined by the Board, there is no minimum period for holding options before they can be exercised under the terms of the Share Option Scheme - Unless otherwise determined by the Board, there is no minimum period for holding the option before it can be exercised under the terms of the Share Option Scheme[75](index=75&type=chunk) [Subscription Price of Shares](index=24&type=section&id=Subscription%20Price%20of%20Shares) The subscription price must be at least the highest of the closing price on the grant date, the average closing price of the preceding five business days, and the nominal value of the share - The subscription price must be at least the highest of: (a) the closing price of the shares as stated in the daily quotation sheet of the Stock Exchange on the date of grant; (b) the average closing price of the shares as stated in the daily quotation sheet of the Stock Exchange for the five business days immediately preceding the date of grant; and (c) the nominal value of the shares[76](index=76&type=chunk) [Amount Payable on Acceptance of Option](index=24&type=section&id=Amount%20Payable%20on%20Acceptance%20of%20Option) Each eligible participant must pay HKD 1.00 to the Company upon accepting an option offer, payable within 21 days from the offer date - Each eligible participant shall pay **HKD 1.00** to the Company upon acceptance of an option offer, which shall be payable within **21 days** from the date of the offer[77](index=77&type=chunk) [Time of Exercise of Option](index=24&type=section&id=Time%20of%20Exercise%20of%20Option) Options may be exercised at any time within the option period notified by the Board to each grantee, but not later than 10 years from the grant date - Options may be exercised at any time within the option period notified by the Board to each grantee, provided that no option shall be exercisable later than **10 years** from the date of grant[78](index=78&type=chunk) [Details of Movements in Share Options](index=25&type=section&id=Details%20of%20Movements%20in%20Share%20Options) As of June 30, 2025, the total number of share options was 21,030,000, with no grants, exercises, lapses, or cancellations during the period Share Option Movements Details | Participant Category/Name | Exercise Price Per Share (HKD) | Grant Date | Balance as of Jan 1, 2025 | Granted During Period | Exercised During Period | Lapsed During Period | Cancelled During Period | Balance as of June 30, 2025 | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Director Guo Xia | 0.450 | June 30, 2015 | 9,150,000 | - | - | - | - | 9,150,000 | | Director Guo Xia | 0.504 | March 24, 2021 | 9,000,000 | - | - | - | - | 9,000,000 | | Ni Binhui | 0.504 | March 24, 2021 | 100,000 | - | - | - | - | 100,000 | | Group Employees | 0.45 | June 30, 2015 | 280,000 | - | - | - | - | 280,000 | | Group Employees | 0.504 | March 24, 2021 | 2,500,000 | - | - | - | - | 2,500,000 | | **Total** | | | **21,030,000** | **-** | **-** | **-** | **-** | **21,030,000** | - No other share options were granted, exercised, cancelled, or lapsed during the period of this announcement[81](index=81&type=chunk) [Corporate Governance](index=26&type=section&id=Corporate%20Governance) [Corporate Governance Practices](index=26&type=section&id=Corporate%20Governance%20Practices) The company's corporate governance practices are based on the principles and code provisions of Appendix 15 of the GEM Listing Rules, emphasizing board quality, transparency, and accountability to shareholders, with deviations in the separation of Chairman and CEO roles and independent non-executive directors' attendance at general meetings - The Company's corporate governance practices are based on the principles and code provisions stipulated in the Corporate Governance Code set out in Appendix 15 of the GEM Listing Rules[82](index=82&type=chunk) - The Company has not appointed a Chief Executive Officer, with daily management handled by executive directors and senior management, which deviates from Code Provision C.2.1 requiring separation of Chairman and Chief Executive Officer roles[82](index=82&type=chunk) - Independent non-executive directors should attend general meetings to gain a full and fair understanding of shareholders' views, and the Board should invite the chairmen of the Audit Committee and other committees to attend annual general meetings to answer questions; the Company has deviations in this regard[82](index=82&type=chunk) [Directors' Securities Transactions](index=26&type=section&id=Directors'%20Securities%20Transactions) The Company adopted a code of conduct for directors' securities transactions no less stringent than GEM Listing Rules, confirming all directors complied during the period - The Company has adopted a code of conduct for directors' securities transactions, the terms of which are no less stringent than the required standards of dealing set out in Rules 5.48 to 5.67 of the GEM Listing Rules[83](index=83&type=chunk) - All directors' securities transactions during this period complied with the required standards of dealing and the code of conduct[83](index=83&type=chunk) [Audit Committee](index=27&type=section&id=Audit%20Committee) The Audit Committee, comprising four independent non-executive directors chaired by Ms. Liu Na, reviews company reports and internal controls, and has reviewed the unaudited consolidated results for the period, deeming them compliant with accounting standards and adequately disclosed - The Audit Committee comprises four independent non-executive directors, namely Ms. Liu Na (Chairperson), Dr. Ni Binhui, Mr. Guo Tong, and Mr. Wu Shuangsi[84](index=84&type=chunk) - Its primary responsibilities are to review the Company's annual reports and accounts, half-yearly reports, and quarterly reports, as well as the Group's internal control systems, and to provide advice and recommendations to the Board[84](index=84&type=chunk) - The Audit Committee has reviewed the Group's unaudited consolidated results for the current period and is of the opinion that they have been prepared in compliance with applicable accounting standards and requirements and have been adequately disclosed[84](index=84&type=chunk) [Sufficiency of Public Float](index=27&type=section&id=Sufficiency%20of%20Public%20Float) As of the announcement date, the Company maintained a sufficient public float - Based on publicly available information and to the best of the Board's knowledge as of the date of this announcement, the Company maintained a sufficient public float[85](index=85&type=chunk) [By Order of the Board](index=27&type=section&id=By%20Order%20of%20the%20Board) [Board Composition](index=27&type=section&id=Board%20Composition) As of the announcement date, the Board comprises two executive directors (Mr. Guo Xia, Mr. Guo Ruimeng), one non-executive director (Dr. Zhang Li), and four independent non-executive directors (Dr. Ni Binhui, Mr. Guo Tong, Mr. Wu Shuangsi, Ms. Liu Na) - As of the date of this announcement, the Board comprises two executive directors (Mr. Guo Xia and Mr. Guo Ruimeng), one non-executive director (Dr. Zhang Li), and four independent non-executive directors (Dr. Ni Binhui, Mr. Guo Tong, Mr. Wu Shuangsi, and Ms. Liu Na)[86](index=86&type=chunk)

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完備性亦無發表聲明，並表明不會就本公告全部或任何部份內容或因倚賴該等 內容而引致之任何損失承擔任何責任。 China Health Group Inc. 香港，二零二五年八月十三日 於本公告日期，董事會成員包括两名執行董事，分別為郭夏先生及郭瑞萌先生；一名非 執行董事，為張麗博士；及四名獨立非執行董事，分別為倪彬暉博士、伍霜駟先生、郭 彤博士及劉娜女士。 本公告載有根據 GEM 上市規則規定須提供有關本公司資料的詳情，董事願就本公佈共同 及個別地承擔全部責任。各董事在作出一切合理查詢後確認，就彼等所知及所信，本公 佈所載的資料在各重大方面乃準確完整,無誤導或欺詐成份，且概無遺漏任何其他事宜 致使本公佈或其所載任何陳述產生誤導。 本公告將於联交所網址 www.hkexnews.hk 之「最新上市公司公告」網頁刊載，由刊載日 期起計為期七日，並於本公司網址 http://www.chgi.net 網頁刊載。 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號: 08225 ...

呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08225 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國醫療集團有限公司 (以「萬全醫療集團」名稱 ...

金十期货7月29日讯，伦敦金属交易所（LME）有色金属注册及注销仓单如下： 1. 铜注册仓单108225吨，注销仓单19400吨，增加2125吨。 2. 铝注册仓单441600吨，注销仓单14500吨，减少475吨。 3. 镍注册仓单195396吨，注销仓单9516吨，减少306吨。 4. 锌注册仓单57600吨，注销仓单54550吨，减少400吨。 5. 铅注册仓单198450吨，注销仓单71900吨，减少1025吨。 6. 锡注册仓单1350吨，注销仓单505吨，增加175吨。 LME注册及注销仓单日报 ...

Core Viewpoint - The Chinese medical group industry is experiencing rapid development and strategic transformation, with a projected revenue of 40.5 billion yuan in 2024, reflecting a year-on-year growth of 27.52%, indicating strong market expansion momentum [1][13]. Industry Overview - Medical groups, also known as "medical practice organizations," consist of multiple doctors forming alliances or independent legal entities, sharing income and risks while providing medical services [2]. - The industry includes internal, external, and cross-system medical groups based on the attributes of the doctors involved [2]. Industry Development History - The industry has gone through three main phases: 1. **Incubation Period (1996-2013)**: The first medical group was established in 1996, but growth was slow due to policy constraints [4]. 2. **Rapid Development (2014-2018)**: The introduction of supportive policies led to a surge in medical groups, with over 1,000 established by 2018 [4]. 3. **Rational Adjustment (2019-Present)**: The industry faced challenges due to increased competition and capital constraints, leading to a focus on online and offline integration [5][6]. Industry Current Status - The industry is in a critical phase of rapid growth and strategic transformation, with significant capital inflow and innovative competition models emerging [1][13]. - Leading institutions like the Ludaopei Medical Group have completed substantial financing, reflecting high market recognition for medical resource integration platforms [1][13]. Industry Value Chain - The upstream of the medical group industry includes medical equipment, pharmaceuticals, medical technology, and human resources, while the downstream consists of patients who receive medical services [8]. Industry Development Trends 1. **Technological Drive and Digital Transformation**: The industry will accelerate the adoption of AI, big data, and telemedicine, creating a blended online and offline healthcare system [21]. 2. **Market Demand Upgrade**: There will be a growing demand for personalized medical services and health management, leading to diversified service models [22]. 3. **Policy Support for Standardization**: Government policies will encourage the development of medical groups, enhancing operational capabilities and brand building [23]. Key Group Profiles - **Zhang Qiang Medical Group**: Established in 2014, focusing on vascular surgery, it has become a pioneer in the industry with multiple specialized teams [15][17]. - **Harteim Heart Medical Group**: Founded in 2015, it specializes in cardiovascular diseases and has established a comprehensive service network across China [15][19]. - **Ludaopei Medical Group**: Focused on hematology, it has rapidly expanded its services nationwide and achieved significant financing [15][17].

2024 CHINA HEALTH GROUP INC. 中國醫療集團有限公司 (Carrying on business in Hong Kong as "萬全醫療集團") (以「萬全醫療集團」名稱在香港經營業務) (Incorporated in the Cayman Islands with limited liability) (於 開 曼 群 島 註 冊 成 立 之 有 限 公 司) (Stock Code: 08225) (股份代號: 08225) ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 截至二零二四年十二月三十一日止 之年度報告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment ...

Financial Performance - For the year ended December 31, 2024, China Health Group Inc. reported revenue of RMB 26,454,000, an increase of 23.3% from RMB 21,425,000 in 2023[10] - The gross profit for the year was RMB 10,067,000, representing a gross margin of approximately 38.0%, compared to RMB 8,212,000 in 2023[10] - The net loss for the year was RMB 14,519,000, significantly reduced from a loss of RMB 58,211,000 in 2023, indicating an improvement of 75.0%[10] - The basic and diluted loss per share improved to RMB 1.46 from RMB 5.83 in 2023, showing a reduction of 75.0%[10] - Loss before taxation for 2024 was RMB 14,519,000, an improvement from a loss of RMB 58,014,000 in 2023[74] - The Group reported a loss before tax of approximately RMB14,473,000 for 2024, significantly reduced from a loss of approximately RMB58,211,000 in 2023[88] - Net loss for the year was approximately RMB14,519,000, compared to a net loss of approximately RMB58,211,000 in 2023[88] Cash and Liquidity - As of December 31, 2024, the Group had cash and cash equivalents of approximately RMB 14,194,000 against current liabilities of approximately RMB 31,243,000, indicating liquidity pressure[14] - The Group's net current assets as of 31 December 2024 were approximately RMB61,393,000, down from approximately RMB77,014,000 in 2023[94] - The Group's total asset-liability ratio remained at 0% as there were no borrowings in both 2023 and 2024[100] - The Group's gearing ratio was nil as of 31 December 2024, indicating no borrowings during the year[95] - The directors believe the Group can finance its operations and meet financial obligations within the forecast period based on cash flow projections[21] - There exists material uncertainty regarding the Group's ability to continue as a going concern due to the financial situation[22] Revenue Sources - Revenue from post-market services increased to RMB 26,454,000 in 2024, up from RMB 17,500,000 in 2023, representing a growth of 51.4%[56] - Total revenue from contracted clinical research services decreased to RMB 0 in 2024, down from RMB 3,925,000 in 2023[56] - Revenue from post-marketing research and academic extension services accounted for approximately 100% of total revenue in 2024, up from 82% in 2023[87] Expenses and Cost Management - Administrative expenses increased to RMB 10,076,000 from RMB 7,606,000, representing a rise of 32.4%[10] - Staff costs decreased to RMB 3,772,000 in 2024 from RMB 4,549,000 in 2023, reflecting a reduction of 17%[68] - Total consolidated administrative expenses for 2024 were approximately RMB24,912,000, down from approximately RMB66,543,000 in the previous year[89] Trade Receivables - Trade receivables from related companies amounted to approximately RMB 48,186,000, with an agreement to settle RMB 18,000,000 during the year ending December 31, 2025[15] - The company reported a significant expected credit loss on trade receivables amounting to RMB 14,807,000 in 2024, down from RMB 57,937,000 in 2023[68] - Approximately RMB32,000,000 of trade receivables were recovered in 2024, while approximately RMB36,000,000 of long-aged trade receivables remain outstanding[90] Business Strategy and Development - The Group is actively controlling operating costs and expects to generate positive cash flows from operations in the foreseeable future[15] - The Group has focused on three major disease areas: brain science, allergies, and viruses, establishing five major specialty brands: Xixin mental psychology, Baimin anti-allergy, Yuejie addiction, Jianshou Anti-Dementia, and Rare Diseases[175] - The Group's strategy has shifted from drug development services to big data and post-marketing clinical research treatment and commercial promotion of five core diseases over the past seven years[175] - The Group aims to build digital research and development clinical research specialties, along with special specialty medical drug clinics and rehabilitation medical services[178] Future Outlook - The Group plans to raise further funds through various means such as bank loans and issuance of new debts to enhance capital reserves for future business development[100] - The directors have a reasonable expectation that the Group has adequate resources to continue operational existence for the foreseeable future[24] - The Group is committed to building a comprehensive medical terminal service complex supported by intelligent digital technology, forming a closed-loop system from research to rehabilitation and cure[178] Corporate Governance and Compliance - The consolidated financial statements have been prepared on a going concern basis[25] - The Group's consolidated financial statements for the year ended December 31, 2024, were reviewed by the Audit Committee and comply with applicable accounting standards[150] - The Group has adopted a share option scheme for eligible participants, enhancing employee engagement and retention[137] Research and Innovation - The Group has actively laid out in the field of artificial intelligence, particularly enhancing competitiveness through the comprehensive layout of Deepseek technology and establishing new companies in Hainan and the Guangdong-Hong Kong-Macao Greater Bay Area[160] - The establishment of digital specialty clinics in collaboration with top medical institutions is underway, enhancing the Group's service offerings[111] - The "RWS Wanquan Center" aims to re-screen existing drugs using big data to find optimal treatments for diseases like stroke and COPD[110]

Financial Performance - For the six months ended June 30, 2024, the group recorded revenue of approximately RMB 18,293,013, an increase of about 21.75% compared to RMB 15,024,938 for the same period in 2023[2] - The group reported a profit before tax of approximately RMB 8,651,000, up approximately 26.22% from RMB 6,854,000 in the same period of 2023[2] - Gross profit for the six months ended June 30, 2024, was RMB 11,982,000, with a gross margin of approximately 65.5%, compared to a gross profit of RMB 9,686,000 and a gross margin of 65% in the same period of 2023[2] - The net profit attributable to the owners of the company for the six months ended June 30, 2024, was RMB 7,353,000, compared to RMB 5,826,000 for the same period in 2023[7] - Basic and diluted earnings per share for the six months ended June 30, 2024, were both 0.74 cents, compared to 0.60 cents for the same period in 2023[7] - The total revenue for the six months ended June 30, 2024, increased by 21.75% compared to the same period in 2023, with PMS revenue also rising by approximately 21.75%[23] - The group reported a net profit attributable to owners of the company of approximately RMB 7,353,000 for the period, compared to RMB 5,826,000 in 2023, indicating a significant increase in earnings[25] - Net profit for the current period was approximately RMB 7,353,000, representing a 26.21% increase from RMB 5,826,000 in the previous year[34] Cash Flow and Assets - Net cash generated from operating activities was RMB 2,883,000, compared to RMB 1,164,000 for the same period in 2023[17] - The total assets as of June 30, 2024, amounted to RMB 120,196,000, an increase from RMB 112,180,000 as of December 31, 2023[16] - The net current assets as of June 30, 2024, were RMB 83,006,000, compared to RMB 77,014,000 as of December 31, 2023[16] - The cash and cash equivalents at the end of the period were RMB 6,858,000, an increase from RMB 4,534,000 at the end of the same period in 2023[17] - The company's net current assets and net assets as of June 30, 2024, were approximately RMB 83,006,000 and RMB 91,536,000, respectively, compared to RMB 77,014,000 and RMB 84,183,000 as of December 31, 2023[34] Dividends and Shareholder Information - The board of directors recommended not to declare any dividends for the six months ended June 30, 2024[2] - The group did not recommend any dividend payment for the period, consistent with the previous year[27] - The board does not recommend the distribution of dividends for the six months ending June 30, 2024, consistent with the previous year[37] - The major shareholder Winsland Agents Limited holds 349,368,873 shares, representing 35.10% of the total[53] - The total number of shares held by the beneficial owner Guo Xia is 132,851,941, which accounts for 13.35% of the total[51] - The beneficial ownership of Bright Excel Assets Limited is 91,915,181 shares, which is 9.23% of the total[53] Corporate Governance - The company has adopted corporate governance practices based on the GEM Listing Rules, emphasizing board quality, transparency, and accountability to shareholders[68] - The company has complied with the trading standards and codes of conduct regarding securities transactions by its directors during the reporting period[69] - The audit committee consists of four independent non-executive directors, ensuring compliance with applicable accounting standards and requirements[70] - The board of directors includes two executive directors and four independent non-executive directors, reflecting a balanced governance structure[71] Operational Focus and Strategy - The group aims to become a comprehensive service provider under an internet architecture in the healthcare sector[19] - The company is focusing on becoming a leader in real-world clinical research services, particularly in five key areas: mental health, neurological diseases, allergic diseases, rare diseases, and viral infections[33] - The company has established a biorepository testing laboratory to support clinical research, particularly for antiviral drug studies[34] - The company is experiencing strong demand for its post-marketing clinical research services, contributing to steady business growth[33] - The company is focusing on clinical research services for traditional Chinese medicine, which is projected to be a market worth over 1 trillion RMB due to the need for re-registration of over 40,000 drug approvals[36] - The company aims to leverage its advantages in Hainan, where it plans to utilize the region's free trade zone status by 2025 to acquire new clients[35] Employee and Compensation Information - The total number of employees as of June 30, 2024, is 41, with total salaries for employees and directors during the period amounting to approximately RMB 2.28 million, an increase from RMB 1.83 million in the same period last year[49] Financial Policies and Risks - The company has no borrowings as of June 30, 2024, and plans to consider raising funds through bank loans, issuing new shares, convertible bonds, or new debt to meet long-term funding needs[34] - The company is closely monitoring foreign exchange risks, with most transactions denominated in RMB[43] - The company has no major investments or capital commitments as of June 30, 2024, maintaining a cautious financial policy[38][39] - The company has not engaged in any significant acquisitions or disposals of subsidiaries or associates during the reporting period[40] - The company has implemented measures to prevent similar financial assistance situations, including enhancing internal supervision and risk assessment processes[32] Stock Options and Incentives - The stock option plan was approved on June 30, 2015, with a validity of 10 years, aimed at incentivizing qualified participants[56] - The stock option exercise price must not be lower than the highest of three specified prices, ensuring fair valuation[58] - The total number of shares available for issuance under the share option plan is 88,947,166 shares, representing 8.94% of the total issued shares as of the interim results announcement date[60] - The maximum number of shares that can be issued upon the exercise of options granted to each eligible participant in any 12-month period is limited to 1% of the issued shares, unless approved by shareholders[60] - The total number of options granted during the specified period is 25,500,000, with a remaining balance of 25,380,000 options as of June 30, 2024[66] - The company has not set any performance targets that must be met prior to the exercise of options, unless decided by the board[61] - There is no minimum holding period required before exercising options under the share option plan, unless determined by the board[62]

1 CHINA HEALTH GROUP INC. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號: 08225) 二零二四年中期業績公告 截至二零二四年六月三十日止六個月 香港聯合交易所有限公司（「聯交所」）GEM 的特色 GEM 之定位，乃為相比起其他在聯交所上市之公司帶有較高投資風險之公司提供一個上市 之市場。有意投資之人士應瞭解投資於該等公司之潛在風險，並應經過審慎周詳之考慮後方作出投 資決定。GEM 之高風險及其他特色表示 GEM 較適合專業及其他經驗豐富投資者。 由於 GEM 上市公司之新興性質，在 GEM 買賣之證券可能會較於主機板買賣之證券承受較 大之市場波動風險，同時無法保證在 GEM 買賣之證券會有高流通量之市場。 香港交易及結算所有限公司及聯交所對本公佈之內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而引致之 任何損失承擔任何責任。 本公佈乃遵照聯交所 GEM 證券上市規則之規定而提供有關中國醫療集團有限公司（「本公 司」） 之資料，本公司各董事（「董事」） ...